Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer

Clinical trial NCT06152471 · UNKNOWN

Trial details

NCT number: NCT06152471
Sponsor: Henrik Lindman
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Early-stage Breast Cancer Diarrhea Adverse Drug Event

Start date: 2023-06-07
Primary completion: 2024-10-31
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.